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Hepatitis delta virus (HDV) contains a circular, viroid-like RNA and the hepatitis delta antigen (HDAg) protein. The viral RNA
is replicated via RNA-dependent RNA synthesis, which is thought to be mediated by host DNA-dependent RNA polymerase
II (pol II). The precise mechanism of HDV RNA replication using RNA as a template remains to be elucidated, although it is
clear that HDAg is involved. We demonstrate here that both SP1-activated and basal pol II transcription are inhibited by
HDAg. This inhibitory effect of HDAg was observed in vivo in transient cotransfection assays as well as in vitro in HeLa
nuclear extracts with purified, recombinant HDAg. The in vitro inhibition of pol II transcription could be reversed with excess
HeLa nuclear extracts. Furthermore, HDAg specifically inhibited pol II-mediated transcription but not pol I- or pol III-mediated
transcription. These results provide support for the model in which HDAg participates in a complex with host cell pol II
transcription factors to mediate pol II-dependent HDV RNA replication, concomitantly inhibiting cellular pol II transcription.
© 1998 Academic Press
INTRODUCTION
Hepatitis delta virus (HDV) belongs to the genus delta-
virus and is a natural subviral satellite of hepatitis B virus
(HBV) (Fields et al., 1996). Interestingly, although HDV
represents a unique class of animal RNA viruses, many
of its characteristics are shared by plant viroids and
virusoids (Dinter-Gottlieb, 1995). HDV is a defective hu-
man pathogen that requires HBV for its transmission
(Rizzetto, 1983). HDV infection can occur as a coinfection
with HBV, frequently resulting in fulminant hepatitis, or as
a superinfection of chronic HBV carriers, resulting in
severe chronic hepatitis and liver cirrhosis (Hoffnagle,
1989). The HDV genome is a small, circular, single-
stranded RNA of about 1.7 kb that possesses a high
degree of internal sequence complementarity. This se-
quence complementarity results in the formation of a
double-stranded, unbranched, rod-like RNA structure
(Kos et al., 1986; Wang et al., 1986; Makino et al., 1987).
The HDV virion consists of the RNA genome complexed
with the only known protein encoded by HDV, the hepa-
titis delta antigen (HDAg), to form the ribonucleoprotein
core, which is surrounded by an envelope containing
hepatitis B surface antigen (HBsAg).
The HDAg exists as two major forms in the liver and
sera of infected patients and animals. The two species
are known as small HDAg (SHDAg) and large HDAg
(LHDAg), and have molecular weights of 24 kDa (195
amino acids) and 27 kDa (214 amino acids), respec-
tively. The two proteins are identical in sequence ex-
cept that LHDAg contains an additional 19 amino acids
at the carboxyl terminus. Both forms are phosphopro-
teins with an RNA-binding activity specific for HDV
RNA (Chang et al., 1988; Lin et al., 1990; Chao et al.,
1991; Hwang et al., 1992). The N terminus of HDAg
contains a stretch of leucine zipper sequence from
amino acids 30 to 51. This coiled-coil domain presents
a very hydrophobic surface and provides HDAg with a
domain that can form protein–protein interactions with
other molecules (Landschultz et al., 1988). Indeed,
HDAg forms dimers and oligomers both with itself and
between SHDAg and LHDAg (Xia and Lai, 1992; Chang
et al., 1993; Wang and Lemon, 1993). Although these
two forms of HDAg have similar biochemical proper-
ties, they have very different biological roles in HDV
replication. SHDAg is required for HDV RNA replica-
tion (Kuo et al., 1989), whereas LHDAg inhibits HDV
RNA replication (Chao et al., 1990) and is required for
virus assembly (Chang et al., 1991; Ryu et al., 1992;
Sureau et al., 1992). The way in which SHDAg partic-
ipates in HDV replication remains unclear. But as
HDAg is the only protein encoded by HDV and it has
no known RNA polymerase activity, HDV requires host
cell proteins for the RNA-dependent RNA replication of
its genome. Currently, it is thought that HDV RNA
replication, similar to the replication of viroids, is car-
ried out by RNA polymerase II (pol II) and modified
cellular transcription factors (Flores, 1989; Macnaugh-
ton et al., 1991; Fu and Taylor, 1993). Since pol II
normally uses DNA as its template, it is possible that
one of the functions of SHDAg is to interact with
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cellular transcription factors (including pol II) in a
manner that enables pol II to use HDV RNA as a
template.
One way to determine whether HDAg interacts with cel-
lular pol II transcription factors is to examine the effect of
HDAg on pol II transcription. Previously, it has been shown
that HDAg can inhibit the gene expression of HBV (Wu et
al., 1991), suggesting that HDAg can interfere with pol II
transcription. However, this work has not, so far, been
reproduced. In this study, we directly assay the effects of
HDAg on pol II transcription in vivo and in vitro. We found
that both SHDAg and LHDAg inhibited cellular pol II tran-
scription in transient transfection experiments as well as in
in vitro transcription reactions. In addition, HDAg-mediated
inhibition of transcription was observed with both activated
and basal promoters. Interestingly, HDAg-mediated inhibi-
tion of transcription was specific for pol II promoters, as pol
I- and pol III-specific promoters were not inhibited by HDAg.
These findings support a model in which SHDAg recruits
cellular pol II transcription factors for HDV RNA replication,
inhibiting cellular pol II transcription as a consequence. In
contrast, the interaction of LHDAg with pol II transcription
factors may competitively inhibit both SHDAg-mediated
HDV replication and cellular pol II transcription.
RESULTS
Expression of HDAg in HeLa cells inhibits
chloramphenicol acetyltransferase (CAT) reporter
expression from both activated and basal promoters
Previous studies have indicated that HDV utilizes host
cell factors to replicate its genome. In particular, a-aman-
itin sensitivity experiments suggest that the cellular pro-
teins involved are RNA pol II transcription factors (Mac-
naughton et al., 1991; Fu and Taylor, 1993). To determine
whether HDAg interacts with cellular pol II transcription
factors to mediate HDV RNA replication, the effect of
HDAg on pol II-mediated gene expression was analyzed.
For these experiments, a CAT reporter fused down-
stream of various regulatory elements for pol II transcrip-
tion was used to quantitate gene expression in the pres-
ence and absence of HDAg. HeLa cells were transiently
cotransfected with a plasmid expressing either SHDAg
or LHDAg under the control of the CMV promoter, and a
CAT reporter plasmid containing an activated promoter
that consisted of a synthetic promoter containing multi-
ple SP1-binding sites upstream of consensus TATA and
initiator (Inr) (Smale and Baltimore, 1989) elements fused
to the CAT gene (Fig. 1A). The CAT assays were per-
formed 48 h after transfection. Figure 1B shows the
average results of three independent experiments (with
duplicate samples within each) in graphical form. The
results show that CAT expression from the activated
promoter-containing CAT plasmid was inhibited approx-
imately twofold in the presence of SHDAg and approxi-
mately sixfold in the presence of LHDAg. A representa-
tive CAT assay is shown beneath the graph (Fig. 1C). The
immunoblot using a polyclonal antibody directed against
the HDAg showed that both LHDAg and SHDAg were
expressed at almost the same level (Fig. 1D). This result
suggests that both the SHDAg and LHDAg could inhibit
pol II-mediated transcription from an activated promoter.
The LHDAg showed the more prominent effects.
To determine whether the observed effect of HDAg on
pol II-mediated transcription was a result of its effects on
SP1 or on basal transcription factors, a reporter plasmid
containing only the consensus TATA and Inr elements
(Fig. 2A) was used. The quantitation of CAT activity with
this promoter was more difficult because the transcrip-
tional activity from the basal promoter construct was
considerably weaker, as expected. Nevertheless, the ex-
pression of SHDAg and LHDAg (Fig. 2D) clearly inhibited
pol II-mediated transcription from this basal promoter
(Figs. 2B and 2C). The extent of inhibition by SHDAg was
comparable to that seen with the activated promoter, but
the extent of LHDAg-mediated inhibition appeared to be
less than that observed with the activated promoter
(compare Figs. 1B and 2B). This result suggests that both
the SHDAg- and LHDAg-mediated inhibition occurred
mainly through interaction with basal transcription fac-
tors. LHDAg may further inhibit transcription through
interaction with SP1 (or SP1-associated factors). Similar
results were obtained when experiments were per-
formed in 293 human embryonic kidney cells (data not
shown).
Expression of HDAg in HeLa cells inhibits
RNA pol II transcription
The above results demonstrated that CAT protein ex-
pression, controlled by the basal and activated promot-
ers for pol II, was inhibited in the presence of either
SHDAg or LHDAg. To determine whether this observa-
tion reflected an effect at the transcriptional or transla-
tional level, primer extension analysis of RNA from tran-
siently transfected cells was performed. Briefly, HeLa
cells were transiently transfected with a plasmid ex-
pressing various amounts of either SHDAg or LHDAg
and a reporter plasmid that contains the activated pol II
promoter described above (consisting of multiple SP1-
binding sites upstream of consensus TATA and Inr ele-
ments). Only the activated promoter-containing reporter
plasmid was used in this experiment because transcrip-
tion as measured by primer extension from the basal
promoter was very weak and difficult to detect.
Figure 3 shows the primer extension analysis of the
RNA isolated from the transfected cells. The primer ex-
tension product corresponding to the transcript initiated
from the synthetic promoter construct was 84 nucleo-
tides long (as indicated by the arrow). The results in Fig.
3A showed that increasing amounts of either SHDAg
(lanes 2–4) or LHDAg (lanes 6–8) resulted in a gradual
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inhibition of transcription from this reporter plasmid.
When 5 mg of plasmid DNA expressing SHDAg or LHDAg
was cotransfected, the SP1-activated pol II transcription
was undetectable in LHDAg-expressing cells (lane 7),
whereas there was still a residual level of transcription in
SHDAg-expressing cells (lane 3), suggesting that LHDAg
had a slightly higher inhibitory activity than SHDAg on
pol II-mediated transcription. To rule out the possibility
that the inhibitory activity observed was due to HDV RNA
sequence, we transfected a mutant construct containing
tandem stop codons within the HDAg open reading
frame (ORF), so that no HDAg was produced from the
expressed RNA (data not shown) (Fig. 3B). The results
showed that this mutant HDAg expression plasmid did
not inhibit transcription of the reporter plasmid (lane 4) in
contrast to plasmids for wild-type SHDAg and LHDAg
(lanes 2 and 3). Similar results were obtained when CAT
activity from these plasmids was measured (data not
shown). Thus, the inhibition of transcription observed in
the presence of cotransfected HDAg-expressing plas-
mids was dependent on the expression of HDAg protein
and not on the presence of elements within the cDNA
sequence of the HDAg-expressing plasmids. These re-
sults combined indicated that both SHDAg and LHDAg
inhibited pol II-mediated transcription from this SP1-ac-
tivated promoter. Both SHDAg and LHDAg also inhibited
FIG. 1. HDAg-mediated inhibition of CAT gene expression under the control of an SP1-activated promoter. HeLa cells were cotransfected with a
CAT reporter plasmid containing the SP1/TATA/Inr promoter (A), together with pcDNA3.1 or plasmids expressing SHDAg or LHDAg under the control
of the CMV promoter. (B) CAT results expressed as the relative percent conversion of [14C]chloramphenicol. The percent conversion for the CAT
reporter transfected in the presence of pcDNA3.1 is set as 100. Standard deviations are also indicated (error bars). (C) A thin-layer chromatogram of
a representative CAT assay. (D) An immunoblot detecting HDAg expression.
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transcription from an SP1-activated promoter containing
only a consensus TATA box without the Inr element (data
not shown). Therefore, the inhibitory effect of HDAg oc-
curs at the level of transcription and not translation.
Purified recombinant HDAg inhibits RNA pol II
transcription in HeLa nuclear extracts
To confirm the above results, the effect of HDAg on pol II
transcription was tested in a cell-free transcription system
using partially purified recombinant SHDAg or LHDAg. For
these experiments, pol II-mediated transcription reactions
were carried out using HeLa nuclear extracts. Three differ-
ent reporter plasmids containing combinations of both ac-
tivated and basal promoter elements were used (Fig. 4B,
top). Recombinant SHDAg and LHDAg were expressed
in bacteria and purified by column chromatography (see
Materials and Methods). Figure 4A shows that SHDAg
was purified to apparent homogeneity as shown by the
single protein band detected by Coomassie blue staining
and immunoblotting using an antibody directed against
HDAg. In contrast, the purified LHDAg existed as multiple
bands, most of which probably represent degradation prod-
FIG. 2. HDAg-mediated inhibition of CAT gene expression under the control of a basal promoter. HeLa cells were cotransfected with a CAT reporter
plasmid containing the TATA/Inr promoter (A), together with pcDNA3.1 or plasmids expressing SHDAg or LHDAg under the control of the CMV
promoter. (B) CAT results expressed as the relative percent conversion of [14C]chloramphenicol. The percent conversion for the CAT reporter
transfected in the presence of pcDNA3.1 is set at 100. Standard deviations are also indicated (error bars). (C) A thin-layer chromatogram of a
representative CAT assay. (D) An immunoblot detecting HDAg expression
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ucts of LHDAg because most of the Coomassie blue-
stained proteins were detected by immunoblotting using a
monoclonal antibody against HDAg. Interestingly, an LH-
DAg-specific Ab (rabbit polyclonal antibody directed
against the C-terminal 19 amino acids unique to LHDAg)
detected only one band in this LHDAg preparation (arrow in
Fig. 4A), and a monoclonal Ab specific for SHDAg (which
recognizes the epitope at the extreme C terminus of
SHDAg; amino acids 186–191) (Hwang and Lai, 1993) also
recognized only one band (arrowhead) (data not shown);
therefore, most of the smaller bands detected in the LHDAg
preparation likely represent C-terminal truncations of
SHDAg. The nature of the largest band is not clear, al-
though it was detected by the polyclonal antibody against
the HDAg. There was also a considerable amount of small
molecules (between 20 and 24 kDa) which were detected
by Coomassie blue staining but not by immunoblotting
(lanes 3 and 4). These proteins could not be removed by
additional purification steps (data not shown). The nature of
these small-molecular–weight proteins is not clear.
The results of in vitro transcription assays in HeLa
nuclear extracts (Fig. 4B) showed that transcription from
either SP1-activated (lanes 1–10) or basal (lanes 11–15)
promoters was inhibited by the addition of increasing
amounts of purified SHDAg. The degree of inhibition
appeared to be comparable for all three promoter con-
structs. The various combinations of SP1 and basal pro-
moter elements did not show additive or synergistic
effects of inhibitory activity of SHDAg. Similarly, the ad-
dition of increasing amounts of partially purified LHDAg
(Fig. 4C) also inhibited both SP1-activated (lanes 1–8)
and basal (lanes 9–12) transcription. The degree of inhi-
bition by LHDAg appeared to be greater than that ob-
served with SHDAg for all three promoters, since less
LHDAg (1 mg) than SHDAg (4 mg) was needed to com-
pletely inhibit transcription (see figure legends). How-
ever, this comparison is not quantitative because the
LHDAg preparation contained many degradation prod-
ucts and probably other contaminants (Fig. 4A).
To establish the specificity of inhibition of pol II transcrip-
tion by HDAg, we purified another highly basic nuclear
protein, hnRNP A1 (which also has RNA-binding proper-
ties), fused to glutathione-S-transferase (GST) from Esche-
richia coli. When this recombinant protein was added to the
cell-free transcription system, no inhibition of transcription
was observed (Fig. 4D). In addition, bovine serum albumin
(BSA) dissolved in the storage buffer for HDAg did not
inhibit transcription (lane 5). Thus, the inhibition of pol II
transcription by HDAg observed in HeLa nuclear extracts
was not due to nonspecific effects of any contaminating
proteins or buffer components. These results combined
suggest that SHDAg and LHDAg inhibit both activated and
basal transcription both in cell-free extracts and in tissue
cultured animal cells.
Addition of HeLa nuclear extracts restores
transcription inhibited by HDAg
The above results indicate that HDAg can inhibit pol
II-mediated transcription. One of the possible explana-
FIG. 3. Inhibition of transcription from an SP1-activated promoter by HDAg in vivo. (A) Increasing amounts of SHDAg-expressing (lanes 2–4) or
LHDAg-expressing (lanes 6–8) plasmids were cotransfected with a constant amount (5 mg) of the SP1/TATA/Inr-containing reporter plasmid into HeLa
cells. The amounts of SHDAg- or LHDAg-expressing plasmids cotransfected were 2 mg (lanes 2 and 6), 5 mg (lanes 3 and 7), and 15 mg (lanes 4 and
8), respectively. The total amount of DNA transfected was kept constant (20 mg) by addition of pcDNA3.1. (B) HeLa cells were cotransfected with 10
mg of the SP1/TATA/Inr-containing reporter plasmid and 15 mg of either SHDAg (lane 1), LHDAg (lane 2), or HDAgStop (lane 4). The total amount of
DNA transfected was kept constant (25 mg) by addition of pcDNA3.1. Transcripts synthesized from the SP1/TATA/Inr-containing reporter plasmid were
detected by primer extension using the TK20 primer (see Materials and Methods). The specific transcript yielded a 84-nucleotide primer extension
product (indicated by an arrow).
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tions for this effect is the interaction of HDAg with a
limiting component(s) of the pol II transcription machin-
ery, thereby modifying or sequestering this component(s)
and preventing it from taking part in transcription. To
examine this possibility, increasing amounts of HeLa
nuclear extracts were added to in vitro transcription
reactions in the presence of an inhibitory amount of
SHDAg or LHDAg. As shown in Fig. 5A, addition of
increasing amounts of HeLa nuclear extracts (lanes 5–7)
restored transcription in proportion to the amount of
HeLa nuclear extracts added. Similarly, increasing
amounts of HeLa nuclear extract also restored transcrip-
tion inhibited by LHDAg in proportion to the amount of
HeLa extracts added (Fig. 5B, lanes 5–7). These results
suggest that the addition of excess HeLa nuclear extract
provided sufficient amounts of the limiting component(s)
required to overcome the inhibitory effect of HDAg.
HDAg specifically inhibits RNA pol II transcription but
not RNA pol I or RNA pol III transcription
The results presented above have addressed HDAg
inhibition of transcription using reporter plasmids that
contain RNA pol II-specific promoters. We then examined
whether HDAg could also inhibit pol I- or pol III-mediated
transcription. This question is important because all the
FIG. 4. Inhibition by HDAg of basal and activated pol II transcription in vitro using HeLa nuclear extracts. (A) Characterization of the purified SHDAg
and LHDAg. Purified SHDAg (lanes 1 and 2) and LHDAg (lanes 3 and 4) were separated by SDS-PAGE and stained with Coomassie blue (lanes 2
and 4), or immunoblotted with a rabbit polyclonal Ab against HDAg. The arrow indicates the band detected by a LHDAg-specific antibody; arrowhead
indicates the band detected by the antibody recognizing the C-terminus of SHDAg (see text). (B and C) Increasing amounts of purified SHDAg or
LHDAg were added to an in vitro transcription reaction using HeLa nuclear extracts. Transcripts were detected by primer extension analysis using
the SP6 promoter primer (see Materials and Methods). (B) For each promoter, the transcription reaction contained no SHDAg (2) or 0.5, 1, 2, and 4
mg each of SHDAg. (C) The transcription reaction contained either no LHDAg (2) or 0.2, 0.5, and 1 mg each of LHDAg for each promoter used. (D)
For GST-hnRNP A1, 0.5 mg and 2.5 mg were used for lanes 2 and 3. Lane 5 contained 16 mg BSA dissolved in the storage buffer for HDAg. DNA
templates used are indicated above the corresponding lanes.
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available evidence suggests that pol II is the enzyme
involved in HDV RNA replication; thus, it would be of
interest to determine whether the HDAg-mediated inhi-
bition is specific for pol II. A human ribosomal RNA
(rRNA) promoter-containing plasmid (prHu3CAT) was
used to test whether HDAg could inhibit pol I transcrip-
tion, and a Drosophila melanogaster tRNAArg promoter-
containing plasmid (pArgMaxi) was used to test whether
HDAg could inhibit pol III transcription. The reporter
plasmids for all three polymerase-specific promoters
were transiently cotransfected with either SHDAg- or
LHDAg-expressing plasmids as in Fig. 3, and the level of
transcription was assayed by primer extension analysis
using primers specific for the different plasmids (Fig. 6).
The results show that both SHDAg and LHDAg inhibited
only pol II transcription (lanes 1–4), but not pol I (lanes
5–8) or pol III (lanes 9–12) transcription.
DISCUSSION
The studies in this paper presented evidence that
HDAg inhibits cellular pol II-mediated transcription. This
was demonstrated using three different assays. First,
gene expression as measured by CAT reporters was
inhibited by HDAg in transient cotransfection experi-
ments in HeLa cells. Second, transcription measured
directly by primer extension was inhibited by HDAg in
transient cotransfection experiments in HeLa cells. Third,
in vitro transcription in HeLa nuclear extracts was inhib-
ited by the addition of recombinant, purified HDAg; this
HDAg-mediated inhibition of transcription could be re-
versed with excess HeLa nuclear extract. Furthermore,
the inhibition of pol II transcription by HDAg was ob-
served with both SP1-activated and basal promoters.
These results are consistent with the previous data that
demonstrated a decrease in cellular RNA synthesis in
HeLa and HepG2 cells, as measured by 3H-uridine in-
corporation, following overnight induction of SHDAg ex-
pression (Cole et al., 1990). That study also showed that
SHDAg expression eventually led to cell death with py-
FIG. 5. Restoration of HDAg-inhibited transcription by excess HeLa
nuclear extracts. In vitro transcription reactions were performed and
analyzed by primer extension as in Fig. 4. (A) Transcription reactions
contained no SHDAg (lanes 1), or 1, 2, and 4 mg of recombinant SHDAg
(lanes 2, 3, and 4). For lanes 5–7, 2 mg of SHDAg was used. The
amounts of HeLa nuclear extract used were as follows: lanes 1–4: 50
mg; lane 5: 75 mg; lane 6: 100 mg; and lane 7: 125 mg. (B) Similar to (A)
except that LHDAg was used. Lane 1: no LHDAg; lanes 2–4: 0.2, 0.5,
and 1 mg each of LHDAg; lanes 5–7: 0.5 mg LHDAg. The amount of
HeLa nuclear extract used was: lanes 1–4: 50 mg; lane 5: 75 mg; lane
6: 100 mg; lane 7: 125 mg.
FIG. 6. Effects of HDAg on pol I, pol II, and pol III transcription. Fifteen
micrograms of SHDAg-expressing (lanes 3, 7, and 11) or LHDAg-
expressing (lanes 4, 8, and 12) plasmids were cotransfected with 10 mg
of the SP1/TATA/Inr-containing reporter plasmid (lanes 1–4), the rRNA
promoter-containing plasmid (lanes 5–8), or the tRNAArg promoter-
containing plasmid (lanes 9–12) into HeLa cells. Transcripts synthe-
sized from the SP1/TATA/Inr-containing reporter plasmid were detected
by primer extension using the TK20 primer; transcripts synthesized
from the rRNA promoter-containing reporter plasmid were detected by
primer extension using the HUCAT-PE primer; transcripts synthesized
from the tRNAArg promoter-containing reporter plasmid were detected
by primer extension using the ArgM58 primer (see Materials and
Methods). The specific transcript for the pol II-, pol I-, and pol III-
specific reporter plasmids yielded 84-, 123-, and 58-nucleotide primer
extension products, respectively. The total amount of DNA transfected
was kept constant (25 mg) by addition of pcDNA3.1.
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knotic nuclei and shrunken eosinophilic cytoplasm, re-
sembling the apoptotic bodies seen in HDV-associated
hepatitis (Cole et al., 1990). Other studies have also
suggested that the hepatocyte injury resulting from HDV
infection may be caused directly by cytotoxic effects of
HDAg (Macnaughton et al., 1990a,b). However, a very
recent study showed that LHDAg can stimulate tran-
scription from several promoter-CAT reporter constructs,
whereas SHDAg did not have any effects (Wei and Ga-
nem, 1998). That study relied exclusively on the measure-
ment of CAT expression and did not directly study RNA
transcription. It is not clear why the results of these
studies were different. One possible cause is the differ-
ence in the cell lines and reporter plasmids used. An-
other possibility is that the HDAg sequences used by
different laboratories may be different, as different HDV
isolates show significant sequence heterogeneity.
The results in this study demonstrate that HDAg inhib-
its both SP1-activated and basal pol II transcription.
Since the degrees of inhibition by SHDAg were similar
for both the activated and basal promoters, both in vivo
and in vitro, the inhibition of SP1-activated transcription
by SHDAg was most likely the result of inhibition of basal
transcription. LHDAg may, in addition, directly inhibit
SP1-activated transcription, possibly by binding to SP1
(or SP1-associated factors) because LHDAg inhibited the
activated transcription more than the basal transcription
in both transfected cells and in vitro transcription reac-
tions (Fig. 4), although the amounts of purified HDAg
used in the in vitro experiments could not be definitively
quantitated. It is unclear why LHDAg would have a
greater inhibitory effect on pol II transcription; it is pos-
sible that the 19 additional amino acids at the C terminus
of LHDAg may directly interact with activated transcrip-
tion factors, such as SP1, or alter the protein conforma-
tion of HDAg, so that it interacts with additional factors.
It should be noted that in in vitro assays, a very large
amount of purified HDAg was required for the inhibition
of pol II transcription (Fig. 4). We have noted that the
purified recombinant HDAg formed aggregates in solu-
tion; as a result, the effective molar quantities of the
HDAg molecules were likely significantly lower than the
apparent molar amounts. Nevertheless, because an
even larger amount of BSA (up to 16 mg) did not inhibit
transcription and the inhibition of pol Ii transcription by
HDAg could be overcome by increased amounts of HeLa
nuclear extracts, the results suggest that this inhibition is
specific for HDAg.
Although we can not completely eliminate the possi-
bility that HDAg exerts its inhibitory activity by binding to
DNA templates, the data presented are more consistent
with the interpretation that SHDAg interacts with cellular
transcription factor(s) and recruits them for HDV RNA
replication and, as a consequence, inhibits their func-
tions in cellular transcription. Our data showed that
HDAg inhibited only pol II not pol I or pol III transcription.
Thus, HDAg is not likely to interact with general tran-
scription factors that are involved in transcription by all
three RNA polymerases, such as TBP. Thus, SHDAg most
likely interacts with pol II-specific transcription factors.
This mechanism of inhibiting cellular transcription is
known as transcriptional squelching (Ptashne, 1988; Gill
and Ptashne, 1988; Sadowski et al., 1988; Triezenberg et
al., 1988) and is thought to have widespread importance
as a mechanism for regulating cell cycle-dependent and
differentiation-specific transcriptional activity in eukary-
otic cells, particularly for those promoters whose activity
is governed by coactivators of low abundance (Cahill et
al., 1994). It is interesting that several viruses have ex-
ploited this mechanism to favor transcription of viral
genes and, at the same time, inhibit host cell transcrip-
tion. For example, the adenovirus E1A protein interacts
with TFIID to inhibit transcription stimulated both by itself
and certain other transcriptional activators (Martin et al.,
1990; Boyer and Berk, 1993), the interaction of the Tax1
protein of human T-cell leukemia virus type 1 (HTLV-1)
with p67SRF causes the aberrant induction of cellular
immediate early genes (Fujii et al., 1992), and the VP16
protein of herpes simplex virus (HSV) interferes with both
basal and activated transcription (Pfitzner et al., 1993).
The poliovirus-encoded protease 3Cpro inhibits cellular
pol II transcription by the proteolytic cleavage of TBP
(Clark et al., 1993), resulting in the loss of binding of TBP
to promoter sequences in vitro (Yalamanchili et al., 1996);
in addition, CREB-activated transcription is inhibited by
3Cpro-mediated cleavage of transcription factor CREB,
leading to a significant loss of its DNA-binding and
transcriptional activity (Yalamanchili et al., 1997).
The role of LHDAg in the inhibition of HDV replication
is thought to occur through oligomerization of LHDAg
with SHDAg to prevent SHDAg from functioning in HDV
replication (Xia and Lai, 1992). The data presented here
suggest that LHDAg also interacts with cellular pol II
transcription factors. This is not surprising as LHDAg
and SHDAg have similar functional domains. Because
LHDAg can not participate in HDV RNA replication, the
squelching of transcription factors by LHDAg will prevent
the transcription factors from being used for either HDV
replication or cellular transcription (i.e., competes with
SHDAg binding via the same interaction domains). Thus,
it is possible that LHDAg inhibits HDV replication not
only by binding to SHDAg, as previously suggested (Xia
and Lai, 1992), but also by interacting with cellular tran-
scription factors. Recently, a cellular protein, Dip, was
found to interact with HDAg and thereby inhibit HDV RNA
replication (Brazas and Ganem, 1996). This may be one
of the targets of HDAg. Identification of the cellular tar-
get(s) through which HDAg functions is the next step
toward understanding the molecular mechanism by
which SHDAg activates and LHDAg inhibits HDV repli-
cation.
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MATERIALS AND METHODS
Cells
HeLa cells were grown at 37°C and 5% CO2 in Dul-
becco’s modified Eagle’s medium (DMEM) supple-
mented with 5 to 10% fetal calf serum (FCS) and penicil-
lin-streptomycin.
Plasmids
The SP1/TATA/Inr-, SP1/Inr-, and TATA/Inr-promoter-
containing plasmids and the CAT reporter plasmids con-
taining the SP1/TATA/Inr or TATA/Inr promoters were a
generous gift from Dr. Steve Smale, UCLA. The reporter
plasmids used for in vitro transcription reactions con-
tained the various synthetic promoter sequences cloned
upstream of SP6 promoter sequences in plasmid pSP72
(Promega) as described previously (Zenzie-Gregory et
al., 1993; Lo and Smale, 1996). The SP1/TATA/Inr reporter
plasmid (Zenzie-Gregory et al., 1993) used for transient
transfection studies contained the SP1/TATA/Inr pro-
moter sequences cloned upstream of HSV-TK-coding se-
quences in plasmid pSVPyTK (Smale and Baltimore,
1989); pSVPyTK contains a simian virus 40 (SV40) origin
of replication, a polyomavirus origin of replication, a
large T-antigen gene, and the herpes simplex virus thy-
midine kinase gene. The CAT reporter plasmids were as
described (Plevy et al., 1997). Plasmids with SP1 se-
quences contain the SV40 21-bp repeats (SP1-binding
sites); plasmids with TATA sequences contain the ade-
novirus major late promoter (Ad MLP) TATA box; plas-
mids with Inr sequences contain the terminal transferase
(TdT) Inr sequence (Smale and Baltimore, 1989).
Expression constructs for SHDAg and LHDAg used for
cotransfection in mammalian cells were pCMVneoSm
and pCMVneoLg, respectively (Jeng et al., 1996). Plasmid
pcDNA3.1 was purchased from Invitrogen. GST-hnRNP
A1 was as described (Li et al., 1997).
Plasmid pHDAgStop was constructed by mutating
codons 4 and 5 of the ORF for HDAg to stop codons by
polymerase chain reaction (PCR). The first primer
spanned the translational start site for HDAg (from nt
1604), with codons 4 and 5 being changed to TAA stop
codons, and contained an upstream HindIII site. The
second primer spanned the end of the HDAg ORF (to nt
958) and contained an upstream XbaI site. PCR amplifi-
cation was carried out using plasmid S18 (Xia and Lai,
1992) as a template, by standard procedures. The PCR
insert was digested with HindIII and XbaI and ligated into
pcDNA3.1.
Plasmid prHu3CAT was a gift of Dr. Lucio Comai, USC,
and is described in Zhai et al. (1997). Plasmid pArgMaxi
(also called pArg 26x36) was a gift of Dr. Debbie Johnson,
USC, and is described in Dingermann et al. (1983).
Construction of HDAg-expression vectors used for
purification of HDAg from E. coli
To construct the SHDAg expression vector, PX9 plas-
mid (Chang et al., 1988), which contains a full-length
SHDAg ORF, was used as the template for PCR amplifi-
cation. A forward primer containing an NdeI site and
59-end of SHDAg ORF (59-TATACATATGAGCCGGTCC-
GAA-39) and a reverse primer containing a BamHI site
and complementary sequence to the 39-end of SHDAg
ORF (39-GTCCCTAAGGGTATCCCTAGGG-59) were used
to amplify the entire ORF of SHDAg. For the LHDAg
expression vector, the same 59-end primer and a BamHI-
containing primer complementary to the 39-end of LH-
DAg ORF (39-ACAGCTGGGGTCACTCCTAGGG-59) were
used. The template used for PCR amplification of the
LHDAg ORF was from a recombinant baculovirus stock
PAcYM1-LHDAg (Hwang et al., 1992). After 25 cycles of
PCR amplification, the amplified ORF was digested with
NdeI and BamHI and subcloned into a PET3a vector that
had been treated with NdeI and BamHI. All the con-
structs were confirmed by DNA sequencing analysis.
DNA transfection
HeLa cells were grown to approximately 60% conflu-
ency in DMEM supplemented with 5 to 10% FCS and
were transfected by a calcium phosphate coprecipitation
method (Graham and van der Eb, 1973; Parker and Stark,
1979). In all experiments, 5 mg of reporter plasmid was
transfected with 15 mg of HDAg-expressing plasmid or
pcDNA3.1 unless otherwise indicated; the total amount
of transfected DNA for all experiments was maintained at
20 mg. At 48 h posttransfection, cells were harvested and
cytoplasmic lysates were prepared for CAT assay anal-
ysis or cytoplasmic RNA was isolated by a Nonidet-P40
lysis method (Smale and Tjian, 1985) for primer extension
analysis as described below.
CAT assay
Cells transiently transfected with various plasmids
were harvested at 48 h posttransfection, rinsed twice in
PBS, and pelleted, and cytoplasmic extracts were pre-
pared by multiple rounds of freeze-thawing to lyse the
cells, followed by centrifugation to remove the nuclei.
CAT assays were performed with 100 mg of total cyto-
plasmic extract protein as described in the Promega
protocol. Quantitation of the conversion of [14C]chloram-
phenicol to its acetylated forms was performed with an
Ambis Radioanalytic Imaging System.
Purification of recombinant HDAg expressed in E. coli
Recombinant PET3a-HDAg was transformed into E.
coli strain BL21DE3 for expression. To purify the SHDAg
protein, E. coli cells were induced with 0.2 mM IPTG at
28°C for 18 h. The cells were harvested and resus-
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pended in buffer A [50 mM Tris-HCl (pH 7.4), 1 mM EGTA,
1 mM EDTA, 0.2 mM phenylmethylsulfonylfluoride
(PMSF), and 10% glycerol] and sonicated. The cell extract
was cleared by centrifugation at 15,000 g for 30 min at
4°C. The SHDAg in the supernatant of the cell extract
was purified using DEAE-cellulose chromatography, cel-
lulose phosphate chromatography, SP-Sepharose HP
chromatography, and gel filtration on Superose 12.
To purify the LHDA, E. coli cells were induced with 0.2
mM IPTG at 37°C for 3 h followed by the same proce-
dures as that used for the purification of SHDAg, with the
following exception. After cellulose phosphate chroma-
tography, LHDAg was further purified with a UNO Cation
Exchange Column (Bio-Rad). Purified SHDAg and LHDAg
were analyzed by SDS-PAGE and immunoblotting. Char-
acterization of the recombinant HDAg will be published
elsewhere. The final concentrations of the purified re-
combinant HDAg were: ;1 mg/ml for SHDAg and ;0.1
mg/ml for LHDAg, as determined by Bradford assay.
In vitro transcription and primer extension analysis
HeLa nuclear extracts were prepared by a modifica-
tion of the method of Dignam et al., (1983) as previously
described (Lo et al., 1991). In vitro transcription reactions
contained 50 mg HeLa nuclear extract and 300 ng su-
percoiled DNA templates as described previously
(Smale and Baltimore, 1989). In reactions containing
HDAg, HDAg was preincubated with HeLa nuclear ex-
tract for 10 to 15 min at 30°C. Following the addition of
rNTPs and DNA template, the reaction was further incu-
bated for 30 min at 30°C. The RNA products were puri-
fied and analyzed by primer extension as described
previously (Smale and Tjian, 1985), using a 32P-labeled
SP6 promoter primer (Promega). Following transient
transfection experiments, cytoplasmic RNA (30 mg) was
analyzed by primer extension using a 32P-labeled oligo-
nucleotide complementary to HSV-TK sequences (TK20
primer) (Zenzie-Gregory et al., 1993). For the pol I-specific
plasmid, primer HUCAT-PE (59-AGAGTTGAGAGGGTACG-
TACG-39) complementary to vector sequences (Zhai et
al., 1997) was used; for the pol III-specific plasmid,
primer ArgM58 (59-TCTTCTGATCCCCGGATCCC-39) com-
plementary to the inserted sequences (underlined) of
pArgMaxi (Dingermann et al., 1983) was used. cDNA
products were visualized by electrophoresis on a 6%
denaturing polyacrylamide gel and then autoradiography
in the presence of an intensifying screen.
Immunoblot analysis
Nuclear pellets of cells (remaining after removal of
cytoplasmic supernatants for CAT assay analysis) were
lysed in Laemmli’s sample buffer (Sambrook et al., 1989)
by boiling for 10 min. Chromosomal DNA was sheared by
passage through a 21-guage needle, and cell debris
removed by microcentrifugation for 10 min. Aliquots of
supernatant were electrophoresed on 15% polyacryl-
amide gels, and proteins transferred to Protran transfer
membranes (Schleicher & Schuell) using a Biorad Semi-
Dry Transfer Cell as per manufacturer’s instructions. Af-
ter transfer, immunoblotting was carried out using rabbit
anti-HDAg polyclonal antibody (Ab) and a chemilumines-
cence detection kit (Boehringer and Mannheim).
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